Ansa Biotechnologies Inc: Valuation, Funding & Investors
Ansa Biotechnologies Inc, headquartered in Emeryville, California, is revolutionizing DNA synthesis through its proprietary enzymatic platform. The company offers a sustainable approach that enables the synthesis of longer and more complex DNA sequences without harsh chemicals, thus preserving DNA integrity. Ansa's innovative technology supports advancements in gene and cell therapy, vaccines, agrigenomics, and synthetic biology, empowering scientists to accelerate discoveries and design at scale. With a commitment to quality and customer satisfaction, Ansa provides sequence-perfect clonal DNA and sequence-verified linear double-stranded DNA fragments, facilitating the industry's transition from genome reading to writing.
Leadership & Board
Latest Estimated Valuation
- Total Amount Raised
- $54M
- Total Funding Rounds
- 1
- Latest Funding Amount
- $54M
- Latest Funding Round
- Series B
Funding Round
| Funding Date | Funding Round | Amount Raised | Post-Money Valuation |
|---|---|---|---|
| Oct 08, 2025 | Series B | $54.40M | ― |
Investors
| Investor Name | Funding Round |
|---|---|
| Fall Line Capital | Series B |
| Black Opal Ventures | Series B |
| Blue Water Life Science Advisors | Series B |
| Cerberus Ventures | Series B |
| Altitude Life Science Ventures | Series B |
| AIM13 | Series B |
Similar Companies
A snapshot of private companies similar to Ansa Biotechnologies Inc, helping you discover and navigate related company profiles.









